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Alzheimer’s disease is the most frequent form of dementia and its incidence is rapidly increasing. Genetic factors are important
determinants of the individual susceptibility to the diseaseand many eﬀorts havebeen made to identify loci and markers involved.
Recent ﬁnding describes the GPR3 gene as a modulator of β-amyloid production, suggesting that perturbation of its activity and
function may contribute to the pathogenesis of AD. Furthermore, the gene is located at chromosome 1, in a region proposed
as a susceptibility locus for the disease. We searched for nucleotide variations in the coding sequence and in the region 5 prime
of it by dHPLC and analysed their distribution in a group of 104 AD patients and 109 age-matched controls. We identiﬁed 5
types ofvariation,two in the putative promoter region (g.27718954A>Gand g.27719102A>T) and the others in exon 2 (c.51C>A,
c.80C>G, and c.771C>T). All of them were equally represented in the two cohorts of the study, thus suggesting the absence of an
associationbetween GPR3 gene and AD in our population.
1.Introduction
Alzheimer’s disease (AD) is the most common neurodegen-
erative disease and animportant cause of illness and death in
the industrialized world [1]. It ofteninitiates with diﬃculties
in remembering new information and gradually progresses
to dementia and loss of normal life abilities. The major
histopathologicalfeaturesareextracellularsenileplaquesand
intracellular neuroﬁbrillary tangles (NFTs), both related to
the deposition of misfolded proteins; beta amyloid (Aβ)i s
the main component of plaques and hyperphosphorylated
tau that of NFTs. A very small proportion of AD cases is
directly linked to genetic variations in three genes coding for
the amyloid precursor protein (APP) on chromosome 21,
presenilin 1 (PSEN1) on chromosome 14, and presenilin2
(PSEN2) on chromosome 1. These genetic forms are collec-
tively deﬁned as early-onset familial AD (EOFAD), since the
disease tends to start earlier than the age of 65, sometimes
even before 30 years of age. Most cases of AD are sporadic,
with less evident familial aggregation and later onset of the
symptoms (late-onset AD, LOAD). The causes of sporadic
AD are not deﬁned yet, but current thinking suggests
that multiple factors, including environment, epigenetics,
and genetics concur in determining the individual risk.
Advancing age is surely the prominent risk factor for LOAD,
but genetics is estimated to determine up to 60–80% of
the individual susceptibility [2]. Both candidate gene and
genome wide association studies (GWASs) have identiﬁed
diﬀerent genes and loci potentially capable of modifying
the predisposition to develop AD; the Apolipoprotein E
gene (APOE) is by large the most important of these, with
carriers of the e4 allele having a 4-fold increased risk [3],
while those of the e2 allele beneﬁt of a protective eﬀect
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Table 1: Demographic, clinical, and genetic characteristics of pa-
tients with AD and controls.
AD CNT P value
n 104 109
Sex F/M 71/33 74/35
Agea,b, years 78.4 ± 6.7 72.6 ± 7.9
MMSE scorea 19.2 ± 5.7 27–30
APOE ε4+ 39.4% 13.2% <.001
aData are given as mean ± SD.
bThe age of onset of the disease was considered for AD patients.
AD: Alzheimer’s disease patients; CNT: controls, MMSE: Mini Mental Scale
Examination.
Recent ﬁndings have indicated the orphan G protein-
coupled receptor 3 (GPR3) has a possible agent in the
modulation of Aβ metabolism [6]. Overexpression of GPR3
stimulated the production of the peptide, while its genetic
ablation reduced it, both in transduced neural cells and
in a mouse model of AD. This eﬀect was exerted through
the modulation of γ-secretase, one of the enzymes involved
in APP proteolytic processing [7]; overexpression of GPR3
determined an increase in the amount of mature γ-secretase
and of its localization at the cellular surface. Interestingly
GPR3 is signiﬁcantly expressed in the central nervous system
[8], is elevated in the sporadic AD brain [6], and maps to
chromosome 1 p36.1–p35 [9], which has been suggested as
a potential AD linkage region in a high-resolution genome
screen [10]. On the basis of these data we scanned the
putative promoter and coding regions of GPR3 gene by
DHPLC and evaluated frequencies and distribution of the
identiﬁed sequence variations in cohorts of Italian AD
patients and age-matched controls.
2.Materialsand Methods
2.1. Patients and Controls. AD patients and controls were
recruited by the Alzheimer Unit of Ospedale Maggiore
in Milan (Italy). All patients (104) underwent a standard
battery of examinations and dementia severity was assessed
by the Clinical Dementia Rating (CDR) and the Mini
Mental Scale Examination (MMSE). The diagnosis of prob-
able AD was made according to NINCDS-ADRDA criteria
[11]. The control group consisted of 109 nondemented
subjects (MMSE ranging from 27 to 30). All individuals or
caregivers provided an informed consent to participate in
genetic studies. Table 1 shows the demographic and clinical
characteristics of the population sample. Considering the
age of onset of the disease, the AD population (78.4 ± 6.7)
had similar age than the control one (72.6 ± 7.9) and no
diﬀerences in gender distribution were present.
2.2. Patients and Controls. Genomic DNA was obtained
from whole blood [12]a n ds t o r e da t4 ◦Cu n t i lu s e .
APOE genotyping was performed by DHPLC as previously
described [13]. Table 1 shows number and percentage of
APOE ε4 carriers among patients and controls. The GPR3
gene consists of two exons separated by a single intron.
Table 2: Nucleotide variantsin GPR3 promoterand coding regions
and their allele frequencies in AD patients and controls.
Allele frequencies
SNP position AD CNT P value
g.27718954A>GU p s t r e a m 5   end 0.084 0.082 1.0
g.27719102A>TU p s t r e a m 5   end 0.084 0.082 1.0
c.51C>A Exon 2 0.026 0.023 .84
c.771C>T Exon 2 0.011 0.010 .89
The g.27718953A>G (rs2504785) and g.27719102A>TS N P sa r ei nt h e
genomic region (NC 000001.10) upstream of GPR3 exon1 and proba-
bly linked in a haplotype (AA or GT). The c.51C>A and c.771C>T
(NM 05821.2) are synonymous SNPs and correspond to Rs11586015
and Rs2230880, respectively. SNP: single nucleotide polymorphism; AD:
Alzheimer’s disease patients; CNT: controls.
The coding sequence (NM 005281.2, from base 1 to base
1324) and about 500 bp upstream of exon 1 (hereafter
referred to as “promoter” region) were analyzed by the
Navigator software (Transgenomic Inc, Neb., USA) in order
to evaluate the melting proﬁles in the sequence and optimize
the design of primers for PCR ampliﬁcation. The sequence
of interest was subdivided in 5 diﬀerent fragments, rang-
ing from 280 to 540bp. About 100ng of genomic DNA
were ampliﬁed by primers and settings described in the
supplementary (Table 1SD, material available online at doi:
10.4061/2011/576143) DHPLC analysis was performed by a
3500A System (Transgenomic Inc, Neb., USA.); 5μLo fe a c h
PCR reaction were loaded on a SepAcolumn and analysed at
the temperatures described in Table 1SD. Diﬀerent elution
proﬁles were obtained and associated to speciﬁc genotypes
byfurtherDHPLCanalysisandsequencing.Finally,homozy-
gous samples always eluted with single-peak, symmetric
proﬁles, with no evident diﬀerences in the retention time. In
order to distinguish wild-type samples from those carrying
mutation in homozygosis, each sample was mixed with
a known wild-type one, denatured and reannealed, and
further analysed by DHPLC; when the elution proﬁle was
no more symmetric, sequencing allowed to conﬁrm the
presence of a homozygous nucleotide variation.
2.3. Patients and Controls. Allelic and genotypic frequencies
were obtainedbydirect counting.The Hardy-Weinbergequi-
librium and diﬀerences in the allele frequency distribution
betweenpatientsandcontrolswere assessed by theχ-squared
test.
3.Resultsand Discussion
The analysis of GPR3 “promoter” and coding regions
by dHPLC in about 400 chromosomes evidenced few
nucleotide variations, most of which with low frequency
(Table 2). We identiﬁed a possible haplotype in the “pro-
moter” region, consisting of the SNPs g.27718954A>G
(rs2504785) and the g.27719102A>T( N C000001.10). All
the subjects carrying the G variant in the most upstream
position were also positive for the second variation.
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they are probably inherited as a haplotype, AA and GT
being the two alternative genotypes. The overall allelic
frequency was 8.3%; ﬁve individuals were homozygous
and 19 heterozygous. No frequency is reported in the
database (Entrez SNP, http://www.ncbi.nlm.nih.gov/)f o r
rs2504785 and the comparison with our data is impos-
sible. The g.27719102A>T seems to be unreported yet.
The analysis of the possible biological eﬀects of the
two SNPs was performed by TFSEARCH (http://www.cbrc
.jp/research/db/TFSEARCH.html) and resulted in no diﬀer-
ence in types and positions of putative transcription factor-
binding sites among the ancestral sequence and the variant
one.
The analysis of the coding sequence (NM 05821.2)
revealedonly three substitutions, two synonymous (Table 2),
c.51C>A (G17G, Rs11586015) and c.771C>T (A257A,
Rs2230880) and one nonsynonymous, c.80c>G (A27G), all
at the heterozygous state. The frequency of the c51C>A
SNP was 0.024, very close to that described in the database
(0.042, pilot 1 CEU sample). That of c.771C>T was 0.010
(database = 0.033, MITOGPOP6 sample), while the third
mutation was identiﬁed in a single subject.
When we compared the distribution of these variants in
thecohortofADpatientsversusthatofage-matchedcontrols
we did not ﬁnd any statistically signiﬁcant diﬀerence, the
frequency being virtually the same in patients and controls
(Table 2).
Since we analysed each amplicon at diﬀerent tempera-
tures, we believe that our search is complete and that the
other types of substitution in GPR3 open reading frame
(rs34890664, rs34585631, and rs734852) that are described
inthedatabasearenotpresentinourpopulation.Asamatter
offacttheirallelicfrequencyiseithernotreportedorverylow
(rs734852 = 0.017, HapMapCEU).
4.Conclusions
The number of subjects enrolled in the study together
with the low incidence of the nucleotide variations found
in GPR3 gene sequence limit the statistical power of the
study (between 40 and 50%, http://www.dssresearch.com/
toolkit/default.asp); nonetheless the results let us infer that
the SNPs identiﬁed do not determine modiﬁcation of the
individual risk to develop AD. The analysis of a larger popu-
lation sample would be useful forthe deﬁnitive conﬁrmation
of the results.
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